Suggested remit: To appraise the clinical and cost effectiveness of amivantamab in combination with carboplatin and pemetrexed within its marketing authorisation for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 5110

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5110 23 May 2024 - 21 June 2024

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 May 2024 In progress. Scoping commenced.
30 November 2023 Please note that following on from advice received from the company this appraisal has been rescheduled. We now anticipate that the appraisal will begin during mid-July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2024.
04 May 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
14 April 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
14 April 2022 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual